| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MAZEMaze Therapeutics, Inc. | 1.92B | 39.81 | 511.70 | 31.18% | -33.24% | 3.91% | 0.14 | |
| GNFTGenfit S.A. | 313.52M | 6.27 | 209 | 134.56% | -14.12% | -31.42% | 4.54% | 0.90 |
| GYREGyre Therapeutics, Inc. | 741.77M | 7.70 | 154 | -6.78% | 6.2% | 4.84% | 0.02 | |
| TVRDTvardi Therapeutics, Inc. | 42.31M | 4.51 | -0.10 | -65.96% | -317.54% | -63.46% | ||
| UNCYUnicycive Therapeutics, Inc. | 134.75M | 6.27 | -1.12 | -100% | -89.15% | 0.10 | ||
| GLTOGalecto, Inc. | 38.32M | 23.95 | -1.29 | -237.68% | 0.00 | |||
| IVAInventiva S.A. | 1.17B | 6.12 | -1.73 | -47.37% | -13.75% | |||
| AKBAAkebia Therapeutics, Inc. | 355.59M | 1.34 | -4.06 | -17.7% | -7.07% | -38.24% |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 1M | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | -1% | - | - |
| Cost of Goods Sold | 65K | 195K | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -65K | -195K | 0 | 1M | 0 | 0 | 0 |
| Gross Margin % | - | - | - | 1% | - | - | - |
| Gross Profit Growth % | - | -2% | 1% | - | -1% | - | - |
| Operating Expenses | 18.45M | 70.2M | 37.02M | 50.86M | 62.03M | 102.56M | 101.87M |
| OpEx % of Revenue | - | - | - | 50.86% | - | - | - |
| Selling, General & Admin | 3.9M | 8.66M | 9M | 19.55M | 22.41M | 39.06M | 31.76M |
| SG&A % of Revenue | - | - | - | 19.55% | - | - | - |
| Research & Development | 14.55M | 61.53M | 28.03M | 31.31M | 39.62M | 63.5M | 70.11M |
| R&D % of Revenue | - | - | - | 31.31% | - | - | - |
| Other Operating Expenses | 38K | 154K | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -18.45M | -70.2M | -37.02M | -49.86M | -62.03M | -102.56M | -101.87M |
| Operating Margin % | - | - | - | -49.86% | - | - | - |
| Operating Income Growth % | - | -2.8% | 0.47% | -0.35% | -0.24% | -0.65% | 0.01% |
| EBITDA | -18.39M | -70M | -36.63M | -49.35M | -61M | -101.68M | -100.97M |
| EBITDA Margin % | - | - | - | -49.35% | - | - | - |
| EBITDA Growth % | - | -2.81% | 0.48% | -0.35% | -0.24% | -0.67% | 0.01% |
| D&A (Non-Cash Add-back) | 65K | 195K | 394K | 512K | 1.03M | 881K | 896K |
| EBIT | -18.45M | -68.84M | -37.02M | -49.86M | -62.03M | -102.56M | -101.87M |
| Net Interest Income | 0 | 1.2M | 55K | 170K | 2.11M | 12.9M | 13.29M |
| Interest Income | 332K | 1.2M | 55K | 170K | 2.11M | 12.9M | 13.29M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 370K | 1.36M | 7.97M | 210K | 2.04M | 12.59M | 13.28M |
| Pretax Income | -18.09M | -68.84M | -29.06M | -49.65M | -59.99M | -89.97M | -88.59M |
| Pretax Margin % | - | - | - | -49.65% | - | - | - |
| Income Tax | -67K | -20K | 813K | 508K | 358K | 239K | 260K |
| Effective Tax Rate % | 0.98% | 1% | 1.01% | 1.01% | 1.01% | 1% | 1% |
| Net Income | -17.71M | -68.82M | -29.35M | -50.16M | -60.34M | -90.21M | -88.85M |
| Net Margin % | - | - | - | -50.16% | - | - | - |
| Net Income Growth % | - | -2.89% | 0.57% | -0.71% | -0.2% | -0.49% | 0.02% |
| Net Income (Continuing) | -18.02M | -68.82M | -29.87M | -50.16M | -60.34M | -90.21M | -88.85M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 14.32M | 14.12M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.74 | -2.74 | -1.61 | -1.98 | -1.67 | -1.27 | -1.12 |
| EPS Growth % | - | -2.7% | 0.41% | -0.23% | 0.16% | 0.24% | 0.12% |
| EPS (Basic) | -0.74 | -2.74 | -1.61 | -1.98 | -1.67 | -1.27 | -1.12 |
| Diluted Shares Outstanding | 23.97M | 25.1M | 25.13M | 25.27M | 36.03M | 71.26M | 79.51M |
| Basic Shares Outstanding | 23.97M | 25.1M | 25.13M | 25.27M | 36.03M | 71.26M | 79.51M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 88.48M | 22.22M | 90.87M | 166.93M | 285.19M | 267.43M | 362.11M |
| Cash & Short-Term Investments | 86.88M | 19.65M | 74.85M | 165.98M | 283.11M | 263.44M | 358.16M |
| Cash Only | 82.52M | 12.33M | 74.85M | 47.7M | 143.24M | 79.93M | 161.44M |
| Short-Term Investments | 4.36M | 7.32M | 0 | 118.28M | 139.88M | 183.51M | 196.72M |
| Accounts Receivable | 0 | 0 | 12.72M | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 162K | 461K | 2.14M | 0 | 2.07M | 3.99M | 3.94M |
| Total Non-Current Assets | 596K | 1.68M | 1.42M | 1.14M | 1.84M | 1.08M | 1.82M |
| Property, Plant & Equipment | 261K | 961K | 1.18M | 1.05M | 1.8M | 1.03M | 1.47M |
| Fixed Asset Turnover | - | - | - | 0.96x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 335K | 719K | 246K | 94K | 37K | 56K | 350K |
| Total Assets | 89.07M | 23.9M | 92.29M | 168.07M | 287.03M | 268.52M | 363.93M |
| Asset Turnover | - | - | - | 0.01x | - | - | - |
| Asset Growth % | - | -0.73% | 2.86% | 0.82% | 0.71% | -0.06% | 0.36% |
| Total Current Liabilities | 2.38M | 4.95M | 22.82M | 6.82M | 8.47M | 11.94M | 15.65M |
| Accounts Payable | 914K | 1.64M | 935K | 2.13M | 1.65M | 2.52M | 2.15M |
| Days Payables Outstanding | 5.13K | 3.06K | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 12.88M | 0 | 0 | 0 | 428K |
| Deferred Revenue (Current) | 0 | 0 | 836K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 127K | 2.1M | 6.68M | 358K | 185K | 5.96M | 8.37M |
| Current Ratio | 37.25x | 4.49x | 3.98x | 24.48x | 33.68x | 22.39x | 23.14x |
| Quick Ratio | 37.25x | 4.49x | 3.98x | 24.48x | 33.68x | 22.39x | 23.14x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 14.47M | 630K | 877K | 947K | 1.61M | 1.21M | 2.41M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 544K | 0 | 919K |
| Deferred Tax Liabilities | 142K | 345K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 14.32M | 285K | 877K | 947K | 1.07M | 1.21M | 1.49M |
| Total Liabilities | 16.84M | 5.58M | 23.7M | 7.77M | 10.08M | 13.15M | 18.06M |
| Total Debt | 0 | 0 | 12.88M | 0 | 1.21M | 603K | 1.35M |
| Net Debt | -82.52M | -12.33M | -61.97M | -47.7M | -142.03M | -79.32M | -160.09M |
| Debt / Equity | - | - | 0.19x | - | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - |
| Total Equity | 86.56M | 18.32M | 68.59M | 160.3M | 276.94M | 255.37M | 345.87M |
| Equity Growth % | - | -0.79% | 2.74% | 1.34% | 0.73% | -0.08% | 0.35% |
| Book Value per Share | 3.61 | 0.73 | 2.73 | 6.34 | 7.69 | 3.58 | 4.35 |
| Total Shareholders' Equity | 72.23M | 4.21M | 68.59M | 160.3M | 276.94M | 255.37M | 345.87M |
| Common Stock | 0 | 0 | 0 | 3K | 5K | 6K | 9K |
| Retained Earnings | -23.25M | -91.86M | -131.91M | -182.07M | -242.42M | -332.63M | -421.48M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 59K | -106K | -124K | -338K | -822K | -19K | -279K |
| Minority Interest | 14.32M | 14.12M | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.07M | -66.22M | -29.81M | -41.83M | -49.11M | -67.39M | -70.02M |
| Operating CF Margin % | - | - | - | -41.83% | - | - | - |
| Operating CF Growth % | - | -2.66% | 0.55% | -0.4% | -0.17% | -0.37% | -0.04% |
| Net Income | -18.02M | -68.82M | -40.57M | -50.16M | -60.34M | -90.21M | -88.85M |
| Depreciation & Amortization | 65K | 195K | 394K | 512K | 1.03M | 881K | 896K |
| Stock-Based Compensation | 234K | 668K | 1.69M | 8.15M | 10.77M | 25.54M | 15.63M |
| Deferred Taxes | 307K | -94K | 693K | 219K | 392K | 141K | 23K |
| Other Non-Cash Items | -307K | -40K | 2.92M | 879K | 81K | -5.21M | -2.09M |
| Working Capital Changes | -352K | 1.87M | 5.06M | -1.43M | -1.04M | 1.48M | 4.38M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 488K | 722K | -1.15M | 1.73M | -722K | 1.15M | -367K |
| Cash from Investing | -4.78M | -3.86M | 6.69M | -119.7M | -22.27M | -37.99M | -12.41M |
| Capital Expenditures | -244K | -900K | -584K | -340K | -275K | -52K | -42K |
| CapEx % of Revenue | - | - | - | 0.34% | - | - | - |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -4.53K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 99.76M | 62K | 85.52M | 134.39M | 167.09M | 41.95M | 164M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 12.05M | 4K | -738K | 10.91M | -158K | 340K | 1.68M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -18.32M | -67.12M | -30.39M | -42.17M | -49.38M | -67.44M | -70.06M |
| FCF Margin % | - | - | - | -42.17% | - | - | - |
| FCF Growth % | - | -2.66% | 0.55% | -0.39% | -0.17% | -0.37% | -0.04% |
| FCF per Share | -0.76 | -2.67 | -1.21 | -1.67 | -1.37 | -0.95 | -0.88 |
| FCF Conversion (FCF/Net Income) | 1.02x | 0.96x | 1.02x | 0.83x | 0.81x | 0.75x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 72K | 178K | 238K | 3K | 28K | 60K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -20.46% | -131.23% | -67.54% | -43.83% | -27.6% | -33.89% | -29.56% |
| Return on Invested Capital (ROIC) | -343.2% | -1049.81% | -440.25% | -62.73% | -37.59% | -49.47% | -42.23% |
| Gross Margin | - | - | - | 100% | - | - | - |
| Net Margin | - | - | - | -5015.8% | - | - | - |
| Debt / Equity | - | - | 0.19x | - | 0.00x | 0.00x | 0.00x |
| FCF Conversion | 1.02x | 0.96x | 1.02x | 0.83x | 0.81x | 0.75x | 0.79x |
| Revenue Growth | - | - | - | - | -100% | - | - |
Terns Pharmaceuticals, Inc. (TERN) grew revenue by 0.0% over the past year. Growth has been modest.
Terns Pharmaceuticals, Inc. (TERN) reported a net loss of $94.4M for fiscal year 2024.
Terns Pharmaceuticals, Inc. (TERN) has a return on equity (ROE) of -29.6%. Negative ROE indicates the company is unprofitable.
Terns Pharmaceuticals, Inc. (TERN) had negative free cash flow of $77.7M in fiscal year 2024, likely due to heavy capital investments.